TH-4000 (Tarloxotinib)

DRUG2 trials

Sponsors

Rain Oncology Inc

Conditions

Metastatic Head-and-neck Squamous-cell CarcinomaNSCLCNon-small Cell Lung CancerNon-squamous NSCLC

Phase 2

Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin

TerminatedNCT02449681

Rain Oncology IncMetastatic Head-and-neck Squamous-cell Carcinoma

Start: 2015-08-31End: 2017-01-31Updated: 2023-01-12

Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients

TerminatedNCT02454842

Rain Oncology IncNon-small Cell Lung Cancer, Non-squamous NSCLC, NSCLC

Start: 2015-06-30End: 2017-01-31Updated: 2023-01-12

Related Papers

A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin.

2022-04-188 citations

Phase 2 study of tarloxotinib bromide (TRLX) in patients (pts) with EGFR-Mutant, T790M-Negative NSCLC progressing on an EGFR TKI.

Journal of Clinical Oncology2016-05-2012 citations

A phase 2 study of tarloxotinib bromide (TRLX) in patients (Pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS).

Journal of Clinical Oncology2016-05-204 citations

Development of biomarkers to guide the clinical development of tarloxotinib bromide, a hypoxia-activated irreversible EGFR/HER2 inhibitor.

Journal of Clinical Oncology2016-05-202 citations

Use of <sup>18</sup>F-HX4 PET/CT to estimate tumor hypoxia enrolled subjects from ongoing Phase 2 trials using tarloxotinib bromide in advanced NSCLC and SCCHN.

Journal of Clinical Oncology2016-05-20

Abstract A67: Preclinical efficacy of tarloxotinib bromide (TH-4000), a hypoxia-activated EGFR/HER2 inhibitor: rationale for clinical evaluation in EGFR mutant, T790M-negative NSCLC following progression on EGFR-TKI therapy

Molecular Cancer Therapeutics2015-12-017 citations

Abstract A66: Preclinical rationale for the ongoing Phase 2 study of the hypoxia-activated EGFR-TKI tarloxotinib bromide (TH-4000) in patients with advanced squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS)

Molecular Cancer Therapeutics2015-12-015 citations